Basics BridgeBio Pharma, Inc. IPO Date: June 24, 2019 Sector: Healthcare Industry: Biotech Market Cap: $10.39B Activated in VL: True Average Daily Range Avg Daily Range: $0.84 | 3.04% Avg Daily Range (30 D): $0.81 | 1.53% Avg Daily Range (90 D): $0.85 | 1.75% Institutional Daily Volume Avg Daily Volume: 1.45M Avg Daily Volume (30 D): 1.53M Avg Daily Volume (90 D): 2.1M Trade Size Avg Trade Size (Sh.): 84 Avg Trade Size (Sh.) (30 D): 60 Avg Trade Size (Sh.) (90 D): 66 Institutional Trades Total Inst.Trades: 6,790 Avg Inst. Trade: $3.03M Avg Inst. Trade (30 D): $4.9M Avg Inst. Trade (90 D): $4.2M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $6.85M Avg Closing Trade (30 D): $16.53M Avg Closing Trade (90 D): $17.2M Avg Closing Volume: 245.98K     News Sep 28, 2025 @ 3:15 PM Acoramidis Begins to Reduce Cumulative Cardiovascu... Source: Bridgebio Pharma Sep 6, 2025 @ 6:30 PM Encaleret Showed Parathyroid Hormone-Independent N... Source: Bridgebio Pharma, Inc. Aug 30, 2025 @ 11:15 AM Acoramidis Demonstrates Statistically Significant ... Source: Bridgebio Pharma, Inc. Aug 6, 2025 @ 11:33 AM Helix Acquisition Corp. II Retains More than 60% o... Source: Globe Newswire Jul 9, 2025 @ 2:58 PM KRAS Inhibitors Market Size Clinical Trials Patent... Source: Globe Newswire Financials   TTM Q2 2025 Q1 2025 Basic EPS $-4.12 $-.95 $-.88 Diluted EPS $-4.12 $-.95 $-.88 Revenue $ 235.81M $ 110.57M $ 116.63M Gross Profit $ 226.84M $ 106.91M $ 113.99M Net Income / Loss $ -785.01M $ -183.76M $ -169.61M Operating Income / Loss $ -656.43M $ -134.28M $ -104.37M Cost of Revenue $ 8.97M $ 3.65M $ 2.64M Net Cash Flow $ 201.59M $ 208.36M $ -140.5M PE Ratio